In a historic moment at Eswatini’s Central Medical Stores, the arrival of the first shipment of lenacapavir marked a significant turning point in HIV prevention in Africa. Developed by Gilead Sciences, this twice-yearly injection has the potential to revolutionize how people protect themselves from infection. The meticulously stacked boxes in the warehouse held more than just medical supplies — they represented years of preparation, collaboration, and dedication by a multitude of partners.
The excitement among the warehouse staff was palpable, albeit understated. The Ministry of Health, NERCHA, AHF Eswatini, the Global Fund, CIFF, Gilead, PEPFAR, and other partners had worked tirelessly to ensure that the supply chains were ready for this groundbreaking delivery. Eswatini, a country with a high HIV prevalence rate, has been a leader in the fight against the epidemic, and the spirit of determination was evident in the warehouse that day.
At the LaMvelase Clinic in Manzini, the impact of this milestone was felt firsthand. The clinic, operated by AHF Eswatini, serves as a beacon of hope for many seeking HIV testing, treatment, and prevention. The discreet nature of the long-acting injectable offers a sense of liberation for individuals who may face challenges with daily oral prevention or traditional prevention methods.
Dr. Nkululeko Dube reflected on the progress that Eswatini has made in its HIV response, surpassing UNAIDS targets and building a robust treatment program. However, he emphasized the importance of strong prevention efforts to continue driving progress and preventing new infections. The arrival of lenacapavir represents a crucial step in closing the remaining gaps in HIV prevention and treatment.
The significance of this moment extends beyond Eswatini, as other countries in sub-Saharan Africa are also preparing to receive their first shipments of lenacapavir. The simultaneous introduction of this cutting-edge prevention tool in low- and middle-income countries alongside high-income countries signals a shift in the historical pattern of delayed access to innovations.
As the global community sets bold goals to reach millions with long-acting PrEP, sustained investment and trust are essential to maintain momentum and drive progress. The success of HIV prevention efforts hinges on collaboration, funding, and a commitment to providing stigma-free care to those in need.
The memory of those unassuming boxes in the warehouse serves as a reminder of the potential and possibility they hold. With bold action, collaboration, and a focus on community needs, the moment witnessed in Eswatini could be the catalyst for ending AIDS worldwide. This transformative moment marks the beginning of a new chapter in the fight against HIV and a step towards achieving a future where scientific advances reach all corners of the globe.
